Announces grant of US patent for EpiSwitchT
3 October 2017
Oxford BioDynamics Plc
("OBD" or the "Company" and, together with its subsidiaries, the "Group")
Oxford BioDynamics announces grant of US patent for its proprietary technology platform, EpiSwitch™
Oxford BioDynamics Plc ("OBD" or the "Company"), a biotechnology company focused on the discovery and development of epigenetic biomarkers based on regulatory genome architecture, for use within the pharmaceutical and biotechnology industry, today announces the grant of a key patent in the United States by the US Patent and Trademark Office (USPTO) covering EpiSwitch™, the Company's novel technology platform.
The US patent, number 9777327, covers OBD's proprietary EpiSwitch™ technology designs for high resolution discovery and monitoring of regulatory conditional chromosome conformation signatures, as part of the regulatory genome architecture. As a biomarker modality, chromosome conformations have been shown to deliver highly informative stratifications of complex patient phenotypes, assist in better disease understanding and target identifications, and show high concordance with complex genetic and gene expression profiles. Predictive and prognostic stratifications developed by OBD on the basis of its proprietary EpiSwitchTM technology already offer significant improvements in patient stratifications, significant de-risking of drug discovery and development, and upgraded regulatory and market protection.
This patent will extend coverage of Oxford BioDynamics' proprietary technology platform, EpiSwitch™, into another important market for the Company. Counterparts to this patent have already been granted in Europe, China, Japan, Australia, Hong Kong, New Zealand, Singapore and South Africa.
Christian Hoyer Millar, CEO of Oxford BioDynamics, commented:
"The US is a key target market for Oxford BioDynamics and we are delighted to announce the grant of this patent covering use of EpiSwitch™ in this region. The grant of this patent in the US is a significant milestone for the Company. It adds further strength to our global intellectual property portfolio as we position the Company for future growth. With a number of significant achievements in patients' stratifications that OBD has delivered already, we welcome this significant milestone as recognition of our proprietary EpiSwitch™ technology. We believe EpiSwitch™ is a valuable and leading industry solution capable of characterising structural modifications to genome architecture that have a profound effect on health."
For further details contact:
|
Oxford BioDynamics Plc |
|
+44 (0)1865 518910 |
|
Christian Hoyer Millar, CEO |
|
|
|
Paul Stockdale, CFO |
|
|
|
|
|
|
|
Stifel Nicolaus Europe Limited |
|
+44 (0)20 7710 7600 |
|
Nominated Advisor and Broker |
|
|
|
David Arch |
|
|
|
Jonathan Senior |
|
|
|
Peter Lees |
|
|
|
Ben Maddison |
|
|
|
|
|
|
|
Shore Capital |
|
+44 (0)20 7408 4090 |
|
Joint Broker |
|
|
|
Bidhi Bhoma |
|
|
|
Edward Mansfield |
|
|
|
|
|
|
|
FTI Consulting |
|
+44 (0)20 3727 1000 |
|
Financial Public Relations Advisor |
|
|
|
Julia Phillips |
|
|
|
Brett Pollard |
|
|
|
Natalie Garland-Collins |
|
|
Notes for Editors
About Oxford BioDynamics Plc
Oxford BioDynamics Plc (AIM: OBD) ("Oxford BioDynamics") is a biotechnology company focused on the discovery and development of epigenetic biomarkers for use within the pharmaceutical and biotechnology industry.
The Company's award-winning, proprietary technology platform, EpiSwitch™, aims to accelerate the drug discovery and development process, improve the success rate of therapeutic product development and take advantage of the increasing importance of personalised medicine.
In particular, EpiSwitch™ can reduce time to market, failure rates and the costs at every stage of drug discovery. Additionally, the technology provides significant insights into disease mechanisms for drug discovery and product re‐positioning programmes, and enables the personalisation of therapeutics for patients in the context of challenging pricing environments where improved clinical outcomes are critical.
Oxford BioDynamics is headquartered in the UK, and listed on the London Stock Exchange's AIM under the ticker "OBD". For more information please visit www.oxfordbiodynamics.com.
This information is provided by RNS
Latest directors dealings
- 2 days ago City of London Investment Group
- 2 days ago Aberdeen Group plc
- 2 days ago NATWEST GROUP
- 2 days ago Ondo Insurtech
- 2 days ago Banco Santander S.A.